CN108949705A - 过氧化物还原酶1结合蛋白及其应用 - Google Patents

过氧化物还原酶1结合蛋白及其应用 Download PDF

Info

Publication number
CN108949705A
CN108949705A CN201810462792.2A CN201810462792A CN108949705A CN 108949705 A CN108949705 A CN 108949705A CN 201810462792 A CN201810462792 A CN 201810462792A CN 108949705 A CN108949705 A CN 108949705A
Authority
CN
China
Prior art keywords
leu
glu
lys
ala
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810462792.2A
Other languages
English (en)
Other versions
CN108949705B (zh
Inventor
汤晓飞
齐墨词
张敏
陈慧
李玲玉
王敏
葛丽华
杨晶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Stomatological Hospital
Original Assignee
Beijing Stomatological Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Stomatological Hospital filed Critical Beijing Stomatological Hospital
Priority to CN201810462792.2A priority Critical patent/CN108949705B/zh
Publication of CN108949705A publication Critical patent/CN108949705A/zh
Application granted granted Critical
Publication of CN108949705B publication Critical patent/CN108949705B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0051Oxidoreductases (1.) acting on a sulfur group of donors (1.8)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716Muscle proteins, e.g. myosin, actin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/001Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y108/00Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01008Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y207/00Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11025Mitogen-activated protein kinase kinase kinase (2.7.11.25), i.e. MAPKKK or MAP3K
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明公开了过氧化物还原酶1结合蛋白及其应用,所述过氧化物还原酶1(Peroxiredoxin 1,Prx1)的结合蛋白包括TXN(Trx)、ASK1、TPM3、CFL1、GTPBP4、DIRAS2、PPP2R1A中的一种或多种。经免疫共沉淀检测分析,所述过氧化物还原酶1的结合蛋白可以与过氧化物还原酶1结合,且尼古丁可以促进两者的结合。在口腔癌前病变如白斑细胞中,所述过氧化物还原酶1的结合蛋白的表达显著提高,且尼古丁可调控结合蛋白的表达。本发明提供的过氧化物还原酶1结合蛋白可作为分子标记物诊断或防治口腔癌前病变如口腔白斑,制备Prx1蛋白结合物,或用于结合、标记、鉴定、富集、分选或纯化Prx1高表达细胞。

Description

过氧化物还原酶1结合蛋白及其应用
技术领域
本发明属于医药生物技术领域,具体涉及过氧化物还原酶1结合蛋白及其应用。
背景技术
口腔癌发病率位于全身肿瘤的第六位,每年全球新发口腔癌约为65万例,死亡病例为35万人。我国是口腔癌高发和高死亡率国家之一,尽管近30年来治疗手段不断改进,但平均5年生存率始终徘徊在50%左右,仍未得到明显改善,严重威胁着人们的生命健康和生存质量。口腔癌的发病是多步骤、多阶段的过程,约70%口腔癌都有明确的癌前病变阶段,若能有效的治疗和干预口腔癌前病变发生及癌变,则能大大降低口腔癌的发病率。
口腔白斑(oral leukoplakia,OLK)是最常见的口腔癌前病变,其每年的发病率为1.36%,单纯白斑的癌变率为4%-17.5%,白斑伴上皮异常增生者癌变率上升到36%,白斑与鳞癌共存的患病率高达60%。平均癌变病程约为8.2年。流行病学研究报道OLK的发生发展与吸烟密切相关。过去30年,不同国家的流行病学调查发现OLK发病率为1.1%-11.7%,而吸烟人群中OLK发病率则增加到3.7%-60.3%。每天吸烟超过20支的人群中,有74.0%患有口腔白斑。吸烟4-10年可诱发伴上皮异常增生的OLK,继续吸烟4-8年则可发生癌变。吸烟的OLK患者在戒烟1-4年后,患癌风险比持续吸烟的OLK患者明显降低,戒烟10年后,其患癌风险与不吸烟者接近。
过氧化物还原酶(peroxiredoxin,Prx)是新近备受学界关注的特异性巯基抗氧化蛋白超家族,广泛存在于原核生物和真核生物中。过氧化物还原酶1(peroxiredoxin 1,Prx1)是家族中含量最多,分布最广的2-Cys型Prx蛋白,主要分布于细胞质和细胞核。Prx1蛋白N端和C端分别含有一个高度保守的半胱氨酸残基(2-Cys),是细胞中氧化还原反应的灵敏的调节器。研究表明Prx1在一些病变和恶性肿瘤中表达异常增高,如糖尿病、食道癌、肝细胞癌、口腔白斑及口腔鳞状细胞癌等,具有增加细胞存活及抗衰老能力,与一些肿瘤的预后密切相关,提示Prx1可能在多种疾病及肿瘤的发生中发挥重要的作用。
Prx1蛋白具有多种功能,主要的功能有:1)抗氧化功能:Prx1以二聚体的形式,发挥过氧化物酶的作用,清除过多的ROS,维持细胞内的氧化还原稳态;2)分子伴侣功能:Prx1以十聚体的形式,作为分子伴侣参与细胞凋亡、增殖、免疫及炎症等多种生理病理过程。
申请人前期研究率先发现吸烟与Prx1表达密切相关,吸烟鳞癌患者、人口腔白斑及小鼠口腔癌前病变等组织中Prx1表达明显增高;Prx1敲除导致口腔癌前病变程度减轻,引起小鼠舌癌前病变及人癌前病变DOK细胞凋亡水平显著升高,MAPK凋亡信号通路相关分子p-JNK及p-p38MAPK表达增高;Prx1通过激活p-NFκB、p65及p-IκBα,促进人口腔鳞癌细胞增殖、侵袭及转移。以上结果提示Prx1促进了烟草相关OLK的发生及癌变。研究烟草相关的口腔白斑细胞中Prx1相互作用蛋白,以期进一步揭示烟草在口腔白斑发生发展中的作用机制,为口腔白斑的诊断和防治提供新的理论依据,这将对防治口腔白斑发生发展,降低口腔癌的发病率具有重要的现实意义。
发明内容
为解决现有技术中存在的技术问题,本发明的目的在于提供Prx1蛋白的结合蛋白及其应用。
本发明提供了一种分子标记物,包含Prx1结合蛋白的一种或多种,所述Prx1结合蛋白为具有如SEQ ID NO.1~7所示的氨基酸序列或如SEQ ID NO.1~7所示的氨基酸序列经替换、缺失或插入一个或多个氨基酸得到的具有相同功能蛋白的氨基酸序列。
进一步地,本发明提供编码所述分子标记物的基因。
所述的基因具有如下任意一种核苷酸序列:
(1)具有如SEQ ID NO.8~SEQ ID NO.14所示的核苷酸序列;
(2)具有如SEQ ID NO.8~SEQ ID NO.14所示的核苷酸序列经一个或多个核苷酸的替换、缺失或插入得到的编码具有相同功能蛋白的核苷酸序列;
(3)在严格条件下,能够与SEQ ID NO.8~SEQ ID NO.14所示的核苷酸序列杂交的编码具有相同功能蛋白的核苷酸序列。
在本发明的具体实施方式中,所述Prx1结合蛋白分别为TXN(Trx,SEQ ID NO.1)、ASK1(SEQ ID NO.2)、TPM3(SEQ ID NO.3)、CFL1(SEQ ID NO.4)、GTPBP4(SEQ ID NO.5)、DIRAS2(SEQ ID NO.6)、PPP2R1A(SEQ ID NO.7)蛋白中的一种或多种。这些蛋白能够与Prx1蛋白结合并相互作用,而Prx1蛋白的表达与多种肿瘤及细胞或组织病变的发生和发展存在相关性,本发明提供的具体实施方式中证明Prx1结合蛋白TXN、ASK1、TPM3、CFL1、GTPBP4、DIRAS2、PPP2R1A在口腔癌前病变细胞中的表达显著提高。
因此,本发明提供所述分子标记物在辅助诊断和/或防治组织病变或肿瘤中的应用。优选地,所述组织病变为口腔癌前病变,所述肿瘤为口腔癌,更优选地,所述口腔癌前病变为口腔白斑,所述口腔癌前病变和口腔癌为尼古丁诱导型。
Prx1蛋白在多种肿瘤及细胞或组织病变中呈现高水平表达,因此,Prx1蛋白结合物以及鉴定Prx1蛋白高表达细胞能够辅助诊断、治疗、预后和研究肿瘤及细胞或组织病变,对相关疾病的防治具有重要的指导意义。
所述防治组织病变或肿瘤为使用Prx1蛋白或Prx1结合蛋白的抑制剂和/或尼古丁中和剂或抑制剂。
因此,进一步地,本发明还提供了所述的分子标记物在制备Prx1蛋白结合物以及在标记、鉴定、富集、分选和/或纯化Prx1高表达细胞中的应用。
另一方面,本发明提供一种制剂,其包含所述的分子标记物。
其中,所述制剂可以为药物或分子标记制剂。
本领域技术人员应该理解,所述药物或分子标记制剂除包含所述分子标记物外,还可以根据需要包含其它辅料或载体。
本发明的有益效果在于:
(1)首次发现了多种Prx1蛋白的结合蛋白,其能够与Prx1蛋白有效结合,从而能够用于辅助诊断和/或防治组织病变或肿瘤;或用于制备Prx1蛋白结合物以及标记、鉴定、富集、分选和/或纯化Prx1高表达细胞。
(2)首次发现口腔癌前病变细胞中Prx1蛋白的结合蛋白的表达显著提高,且其表达受尼古丁的调控,从而能够用于辅助诊断和/或防治口腔癌前病变或口腔癌,尤其是尼古丁诱导的口腔癌前病变或口腔癌。
附图说明
图1为免疫共沉淀(co-immunoprecipitation,Co-IP)结合SDS-PAGE检测结果。
图2为SDS-PAGE凝胶中提取的Prx1结合蛋白(其中一部分)的质谱鉴定结果。
图3为尼古丁处理组和未经处理组的Prx1结合蛋白的维恩图。
图4为尼古丁处理组和未经处理组共有的结合蛋白和尼古丁处理组特有的结合蛋白生物信息学分析流程示意图。
图5为GO-Analysis分析结果柱状图展示图,其中,图5A、图5B和图5C分别为尼古丁处理组独有的结合蛋白生物学过程、分子功能、细胞组分的GO分析结果,图5D、图5E和图5F为尼古丁处理组和未经处理组共有的结合蛋白生物学过程、分子功能、细胞组分的GO分析结果。
图6为Pathway分析结果,其中,图6A和图6B分别为尼古丁处理组独有的结合蛋白和尼古丁处理组和未经处理组共有的结合蛋白Pathway富集分析柱状图,图6C和图6D分别为尼古丁处理组独有的结合蛋白和尼古丁处理组及未经处理组共有的结合蛋白Pathway显著性水平柱状图。
图7为PPI network分析结果。
图8为对筛选出的结合蛋白采用免疫共沉淀进行验证结果,其中Input代表总蛋白组,IP代表免疫共沉淀组,IgG代表阴性对照组,+代表加入尼古丁处理,-代表未加尼古丁处理。
图9为采用HE染色对小鼠舌黏膜病变程度进行诊断并采用免疫组化染色(×200)检测ASK1、TXN、CFL1在各组小鼠黏膜中的表达,对各组间MOD值进行比较,其中A为小鼠舌黏膜不同病变程度HE染色示意图,B为ASK1免疫组化染色结果,C为TXN免疫组化染色结果,D为CFL1免疫组化染色结果。
图10为采用免疫组化染色(×200)检测PPP2R1A、TPM3、GTPBP4、DIRAS2在各组小鼠黏膜中的表达,对各组间MOD值进行比较,其中A为PPP2R1A免疫组化结果,B为TPM3免疫组化结果,C为GTPBP4免疫组化结果,D为DIRAS2免疫组化结果。
具体实施方式
下面将结合实施例对本发明的优选实施方式进行详细说明。需要理解的是以下实施例的给出仅是为了起到说明的目的,并不是用于对本发明的范围进行限制。本领域的技术人员在不背离本发明的宗旨和精神的情况下,可以对本发明进行各种修改和替换。
下述实施例中所使用的实验方法如无特殊说明,均为本领域技术人员所掌握的常规实验操作。所用试剂若未特别说明,均为商业渠道购买获得。
实施例中所用到的主要研究方法包括利用免疫共沉淀(co-immunoprecipitation,Co-IP)结合质谱鉴定的方法分析未经处理和经1μmol/L尼古丁处理7天的DOK细胞中Prx1结合蛋白,分析出两组共有的结合蛋白和尼古丁处理组特有的结合蛋白,绘制维恩图,对以上结合蛋白进行生物信息学分析,包括GO分析、kegg pathway分析,PPI蛋白互作网络分析,筛选出的结合蛋白采用免疫共沉淀结合western blot检测的方法进行验证。利用申请人前期构建的动物模型标本,采用免疫组化实验方法从蛋白质水平检测验证出的结合蛋白在小鼠舌组织中的表达。
实施例中部分材料和试剂说明如下:
人口腔癌前病变细胞株DOK细胞(美国北卡罗来纳州中央大学陈晓欣教授惠赠);高糖达尔伯克改良伊格尔培养基(Dulbecco’s modified Eagle’s medium,DMEM)、磷酸盐缓冲液(phosphate buffered saline,PBS)、胎牛血清、青霉素及链霉素(Hyclone,美国);0.25%胰蛋白酶(Gibco,美国);尼古丁(wako,日本);苯甲基磺酰氟(phenylmethanesulfonylfluoride,PMSF)、蛋白酶抑制剂(protease inhibitorcocktail,PIC)、蛋白A琼脂糖珠(Sigma,美国);Bradford法蛋白质定量试剂盒、封闭洗涤缓冲液、电泳缓冲液、β-肌动蛋白(β-actin)抗体(北京普利莱基因技术有限公司);Prxl抗体(Abcam,美国);TXN抗体(Abcam,美国);ASK1抗体(Abcam,美国);TPM3抗体(Abcam,美国);CFL1抗体(Abcam,美国);GTPBP4抗体(Abcam,美国);DIRAS2抗体(Abcam,美国);PPP2R1A抗体(Abcam,美国);正常兔IgG(Santa Cruz,美国);预制胶、转印包、脱脂牛奶粉、双色预染蛋白Marker(Bio-Rad.美国);免疫共沉淀(co-immunoprecipitation,Co-IP)裂解液、羊抗兔二抗、羊抗鼠二抗、Co-IP检测试剂、电化学发光液(Pierce,美国);Cell Lysis Buffer(FNN0021,Life technologies);100×蛋白酶抑制剂混合液(#11-10601,SinoGene);Protein A/G-Agarose(A10001,Ab-mart);粉剂型柠檬酸盐修复液、粉剂型PBS磷酸盐缓冲液,粉剂型柠檬酸盐抗原修复液、3%过氧化氢溶液、封闭用正常羊血清原液、通用型二抗、DAB显色液(迈新生物技术开发有限公司,福州)。
实施例1Prx1结合蛋白的初步鉴定
采用免疫共沉淀(co-immunoprecipitation,Co-IP)结合SDS-PAGE检测未经处理和经1μmol/L尼古丁处理7天的DOK细胞中的Prx1结合蛋白,具体操作如下:
(1)100mm的细胞培养皿放在冰上,用冷的PBS洗涤一次,倒掉PBS,加入1ml预冷的Lysis Buffer,用细胞刮铲刮掉细胞,收集细胞,转移到预冷的2ml离心管里。
(2)在步骤1)收集的细胞中加入10μl 100×蛋白酶抑制剂及磷酸酶抑制剂,在冰上放置40min,每10min涡旋一次。
(3)4℃,15300rpm离心40min,收集上清,得到可溶性全蛋白,冰上放置备用。
(4)准备细胞全蛋白,调整至1μg/μl,500μl,加入抗体(Ab),放在15rpm的涡旋仪上,4℃孵育过夜。
(5)取50μl到beads一个1.5ml离心管里,加入1ml PBS,漂洗beads。
(6)3000rpm,离心,去除上清,重复漂洗2次,加入50μl PBS重新悬浮beads。
(7)把制备好的beads加入步骤2的蛋白+Ab的混合液里,放在15rpm的涡旋仪上,4度孵育4h。
(8)3000rpm,离心1min,去除上清,保留proteinA+G beads+Ab+protein,加入1mlPBS,漂洗复合物,保留proteinA+G beads+Ab+protein,PBS漂洗3遍。
(9)加入30μl 1xSDS-PAGE Loading Buffer到beads-Ab-Protein里,沸水煮样品10min,离心,转移上清到新的离心管。
(10)SDS-PAGE检测:IP上样15μl,首先90V电泳30min,后120V电泳2h,取下胶,考马斯亮蓝染色脱色分析。
实验结果:结合SDS-PAGE检测结果(图1),标记为A的样品(尼古丁组)能看到5个明确的蛋白条带,标记为B(对照组)的样品,无明显蛋白条带,对尼古丁组和对照组中分离的结合蛋白进行质谱鉴定(图2),分析出两组共有的结合蛋白和尼古丁处理组特有的结合蛋白,绘制维恩图(图3)。
实施例2采用生物信息学方法分析Prx1结合蛋白
对实施例1中检测得到的Prx1结合蛋白进行生物信息学分析,主要包括GO分析,kegg pathway分析,PPI蛋白互作网络分析(图4)。
(1)GO分析是基于基因注释数据库,检测差异基因显著功能的手段,具体说明如下。
①将尼古丁处理组特有的、两者共有的基因分别基于数据库分别从生物学过程、分子功能、细胞组分三个层面进行GO注释。
②将上述操作得到基因参与的所有GO,采用Fisher检验计算每个GO的显著性水平(P-Value),从而筛选出基因富集的显著性GO。
③显著性的P-Value<0.05用灰白相间的表格标出。
实验结果:通过GO分析可以粗略了解差异基因富集在基因表达、多聚RNA结合以及外泌体方面,结果见图5。
(2)Pathway分析,是基于基因注释数据库,检测差异基因显著Pathway的手段,
①将尼古丁处理组独有的、两者共有的基因分别基于KEGG数据库进行Pathway注释。
②将得到基因参与的所有Pathway Term,采用Fisher检验计算Pathway的显著性水平(P-Value),从而筛选出基因富集的显著性Pathway Term。
③显著性的P-Value<0.05用灰白相间的表格标出。
实验结果:通过Pathway分析,可以看出实验条件下显著改变的代谢通路为核糖体和三羧酸循环途径,具体结果见图6。
(3)KEGG是系统分析基因功能、基因组信息数据库,它有助于研究者把基因及表达信息作为一个整体网络进行研究,说明如下:
①将KEGG组分编号或KEGG的KO号输入KEGG数据库进行预测得到Keggmap。
②以并集基因为研究对象,将其参与的信号转导通路图片信息下载。
(4)PPI,是对蛋白与蛋白、基因与基因间相互作用关系网络构建的结果
①根据分析要求从两者共有的基因GO分析结果中选出与凋亡、侵袭相关的基因。
②以与凋亡、侵袭相关的基因为研究对象,通过NCBI数据库对蛋白互作关系进行检索分析,构建蛋白间互作关系网络。
实验结果:PPI分析结果见图7。
实施例3对筛选出的Prx1结合蛋白进行验证
主要包括两个方面:采用免疫共沉淀(Co-IP)结合Western Blot方法对筛选出的结合蛋白进行验证;采用免疫组化实验方法从蛋白质水平检测验证的结合蛋白在小鼠舌组织中的表达。
(1)采用Co-IP结合Western Blot方法对筛选出的结合蛋白进行验证Co-IP实验按如下步骤进行:
①用预冷的PBS洗细胞2次,刮刀收集细胞。
②加入1ml免疫共沉淀裂解液(含PMSF、PIC),冰上裂解15min。
③4℃、14 000r/min(离心半径9.5cm)离心15min,取上清液。
④使用Bradford法蛋白质定量试剂盒测定蛋白浓度,留取25μg总蛋白。
⑤将剩余的上清液平均分为Prxl Co-IP组(IP组)和阴性对照组(IgG组),IP组中加入0.5μg Prxl抗体,IgG组中加入0.5μg正常兔IgG,旋转摇床4℃过夜。
⑥加入40μl蛋白A琼脂糖珠,旋转摇床4℃孵育4h。
⑦6 000r/min(离心半径9.5cm)离心1min,去上清液。
⑧使用裂解液洗涤沉淀复合物3次,加入30ul 2倍蛋白上样缓冲液,95℃煮沸5min。
⑨4℃、14 000r/min(离心半径9.5cm)离心1min,取上清液,与留取的总蛋白一起进行蛋白质印迹法检测。
Western Blot实验按如下步骤进行:
①新鲜配制电泳液,将预制胶与固定板组装于电泳槽内。
②取25μg总蛋白和适量免疫共沉淀所得蛋白复合物进行十二烷基硫酸钠-聚丙烯酰胺凝胶电泳,电压80V,跑胶2h,半干转7min。
③取出聚偏氟乙烯(polyvinylidenefluorid,PVDF)膜,封闭洗涤缓冲液(Tris-HClTween,TBST)洗膜3次,每次5min。
④5%脱脂牛奶封闭1h。
⑤配制一抗(GTPBP4 1:2 000,DIRAS2 1:200,PPP2R1A 1:1 000,TPM3 1:1 000、TXN 1:500,CFL 1:1 000,ASK1 1:500,β-肌动蛋白:1:1 000,Prxl:1:5 000)4℃摇床孵育过夜,TBST洗膜3次,每次5min。
⑥配制工作浓度的二抗(1:5000),室温摇床孵育1h,TBST洗膜3次,每次10min。
⑦新鲜配制发光液,暗室显影。
实验结果:尼古丁对DOK细胞中TXN、ASK1、TPM3、CFL、GTPBP4、DIRAS2、PPP2R1A和Prxl蛋白结合的影响;Co-IP结果显示,对照组和尼古丁组DOK细胞中TXN、ASK1、TPM3、CFL、GTPBP4、DIRAS2、PPP2R1A与Prxl蛋白均存在结合,尼古丁组结合量高于对照组(图8)。
(2)采用免疫组化法检测结合蛋白在小鼠舌白斑组织中的表达
课题组前期构建了Prx1基因敲除小鼠,采用4NQO饮水法在野生型小鼠和敲除型小鼠舌部建立了口腔白斑模型,并通过涂抹尼古丁的方式模拟吸烟刺激,实验共分为6组,即野生型对照组、4NQO组、4NQO+尼古丁组,敲除型对照组、4NQO组、4NQO+尼古丁组。本实验使用课题组前期建立的口腔白斑动物模型舌组织标本进行后续实验。采用免疫组化实验从蛋白质水平检测上述各组小鼠舌组织中结合蛋白的表达情况。
免疫组化实验方法实验按如下步骤进行:
①将组织切片放在60℃恒温箱中烘烤60分钟。
②分别置于二甲苯I、Ⅱ、III中浸泡10min,无水乙醇I、Ⅱ中浸泡5min,95%乙醇I、Ⅱ中浸泡5min。PBS洗三次,每次5min。
③微波热修复:将组织切片置于柠檬酸钠抗原修复液微波炉中高火处理4min,中火处理6min,自然晾至室温。
④滴加过氧化氢,湿盒内室温孵育15min,PBS洗三次,每次5min。
⑤滴加10%山羊血清封闭液,湿盒内37℃孵育30min。
⑥甩去多余液体滴加一抗,湿盒内4℃过夜。PBS洗三次,每次5min。
⑦滴加生物素化二抗,湿盒内室温孵育30min,PBS洗3次每次5min。
⑧DAB显色,苏木素复染。
⑨脱水、透明、封片、镜检。
实验结果:结果表明与对照组相比,舌口腔白斑中TXN、ASK1、TPM3、CFL1、GTPBP4、DIRAS2、PPP2R1A的表达均升高;尼古丁可促进舌口腔白斑中TXN、TPM3、CFL1、GTPBP4、DIRAS2的表达,抑制ASK1、PPP2R1A的表达,差异有统计学意义;Prx1敲除导致小鼠舌口腔白斑中ASK1、PPP2R1A、CFL1的表达明显升高,TXN、GTPBP4、DIRAS2的表达明显降低,提示所筛选出的Prx1结合蛋白在口腔白斑发生发展中发挥重要作用。具体结果见图9、图10。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明技术原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
序列表
<110> 首都医科大学附属北京口腔医院
<120> 过氧化物还原酶1结合蛋白及其应用
<130> KHP181112281.5
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 105
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Met Val Lys Gln Ile Glu Ser Lys Thr Ala Phe Gln Glu Ala Leu Asp
1 5 10 15
Ala Ala Gly Asp Lys Leu Val Val Val Asp Phe Ser Ala Thr Trp Cys
20 25 30
Gly Pro Cys Lys Met Ile Lys Pro Phe Phe His Ser Leu Ser Glu Lys
35 40 45
Tyr Ser Asn Val Ile Phe Leu Glu Val Asp Val Asp Asp Cys Gln Asp
50 55 60
Val Ala Ser Glu Cys Glu Val Lys Cys Met Pro Thr Phe Gln Phe Phe
65 70 75 80
Lys Lys Gly Gln Lys Val Gly Glu Phe Ser Gly Ala Asn Lys Glu Lys
85 90 95
Leu Glu Ala Thr Ile Asn Glu Leu Val
100 105
<210> 2
<211> 1374
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Met Ser Thr Glu Ala Asp Glu Gly Ile Thr Phe Ser Val Pro Pro Phe
1 5 10 15
Ala Pro Ser Gly Phe Cys Thr Ile Pro Glu Gly Gly Ile Cys Arg Arg
20 25 30
Gly Gly Ala Ala Ala Val Gly Glu Gly Glu Glu His Gln Leu Pro Pro
35 40 45
Pro Pro Pro Gly Ser Phe Trp Asn Val Glu Ser Ala Ala Ala Pro Gly
50 55 60
Ile Gly Cys Pro Ala Ala Thr Ser Ser Ser Ser Ala Thr Arg Gly Arg
65 70 75 80
Gly Ser Ser Val Gly Gly Gly Ser Arg Arg Thr Thr Val Ala Tyr Val
85 90 95
Ile Asn Glu Ala Ser Gln Gly Gln Leu Val Val Ala Glu Ser Glu Ala
100 105 110
Leu Gln Ser Leu Arg Glu Ala Cys Glu Thr Val Gly Ala Thr Leu Glu
115 120 125
Thr Leu His Phe Gly Lys Leu Asp Phe Gly Glu Thr Thr Val Leu Asp
130 135 140
Arg Phe Tyr Asn Ala Asp Ile Ala Val Val Glu Met Ser Asp Ala Phe
145 150 155 160
Arg Gln Pro Ser Leu Phe Tyr His Leu Gly Val Arg Glu Ser Phe Ser
165 170 175
Met Ala Asn Asn Ile Ile Leu Tyr Cys Asp Thr Asn Ser Asp Ser Leu
180 185 190
Gln Ser Leu Lys Glu Ile Ile Cys Gln Lys Asn Thr Met Cys Thr Gly
195 200 205
Asn Tyr Thr Phe Val Pro Tyr Met Ile Thr Pro His Asn Lys Val Tyr
210 215 220
Cys Cys Asp Ser Ser Phe Met Lys Gly Leu Thr Glu Leu Met Gln Pro
225 230 235 240
Asn Phe Glu Leu Leu Leu Gly Pro Ile Cys Leu Pro Leu Val Asp Arg
245 250 255
Phe Ile Gln Leu Leu Lys Val Ala Gln Ala Ser Ser Ser Gln Tyr Phe
260 265 270
Arg Glu Ser Ile Leu Asn Asp Ile Arg Lys Ala Arg Asn Leu Tyr Thr
275 280 285
Gly Lys Glu Leu Ala Ala Glu Leu Ala Arg Ile Arg Gln Arg Val Asp
290 295 300
Asn Ile Glu Val Leu Thr Ala Asp Ile Val Ile Asn Leu Leu Leu Ser
305 310 315 320
Tyr Arg Asp Ile Gln Asp Tyr Asp Ser Ile Val Lys Leu Val Glu Thr
325 330 335
Leu Glu Lys Leu Pro Thr Phe Asp Leu Ala Ser His His His Val Lys
340 345 350
Phe His Tyr Ala Phe Ala Leu Asn Arg Arg Asn Leu Pro Gly Asp Arg
355 360 365
Ala Lys Ala Leu Asp Ile Met Ile Pro Met Val Gln Ser Glu Gly Gln
370 375 380
Val Ala Ser Asp Met Tyr Cys Leu Val Gly Arg Ile Tyr Lys Asp Met
385 390 395 400
Phe Leu Asp Ser Asn Phe Thr Asp Thr Glu Ser Arg Asp His Gly Ala
405 410 415
Ser Trp Phe Lys Lys Ala Phe Glu Ser Glu Pro Thr Leu Gln Ser Gly
420 425 430
Ile Asn Tyr Ala Val Leu Leu Leu Ala Ala Gly His Gln Phe Glu Ser
435 440 445
Ser Phe Glu Leu Arg Lys Val Gly Val Lys Leu Ser Ser Leu Leu Gly
450 455 460
Lys Lys Gly Asn Leu Glu Lys Leu Gln Ser Tyr Trp Glu Val Gly Phe
465 470 475 480
Phe Leu Gly Ala Ser Val Leu Ala Asn Asp His Met Arg Val Ile Gln
485 490 495
Ala Ser Glu Lys Leu Phe Lys Leu Lys Thr Pro Ala Trp Tyr Leu Lys
500 505 510
Ser Ile Val Glu Thr Ile Leu Ile Tyr Lys His Phe Val Lys Leu Thr
515 520 525
Thr Glu Gln Pro Val Ala Lys Gln Glu Leu Val Asp Phe Trp Met Asp
530 535 540
Phe Leu Val Glu Ala Thr Lys Thr Asp Val Thr Val Val Arg Phe Pro
545 550 555 560
Val Leu Ile Leu Glu Pro Thr Lys Ile Tyr Gln Pro Ser Tyr Leu Ser
565 570 575
Ile Asn Asn Glu Val Glu Glu Lys Thr Ile Ser Ile Trp His Val Leu
580 585 590
Pro Asp Asp Lys Lys Gly Ile His Glu Trp Asn Phe Ser Ala Ser Ser
595 600 605
Val Arg Gly Val Ser Ile Ser Lys Phe Glu Glu Arg Cys Cys Phe Leu
610 615 620
Tyr Val Leu His Asn Ser Asp Asp Phe Gln Ile Tyr Phe Cys Thr Glu
625 630 635 640
Leu His Cys Lys Lys Phe Phe Glu Met Val Asn Thr Ile Thr Glu Glu
645 650 655
Lys Gly Arg Ser Thr Glu Glu Gly Asp Cys Glu Ser Asp Leu Leu Glu
660 665 670
Tyr Asp Tyr Glu Tyr Asp Glu Asn Gly Asp Arg Val Val Leu Gly Lys
675 680 685
Gly Thr Tyr Gly Ile Val Tyr Ala Gly Arg Asp Leu Ser Asn Gln Val
690 695 700
Arg Ile Ala Ile Lys Glu Ile Pro Glu Arg Asp Ser Arg Tyr Ser Gln
705 710 715 720
Pro Leu His Glu Glu Ile Ala Leu His Lys His Leu Lys His Lys Asn
725 730 735
Ile Val Gln Tyr Leu Gly Ser Phe Ser Glu Asn Gly Phe Ile Lys Ile
740 745 750
Phe Met Glu Gln Val Pro Gly Gly Ser Leu Ser Ala Leu Leu Arg Ser
755 760 765
Lys Trp Gly Pro Leu Lys Asp Asn Glu Gln Thr Ile Gly Phe Tyr Thr
770 775 780
Lys Gln Ile Leu Glu Gly Leu Lys Tyr Leu His Asp Asn Gln Ile Val
785 790 795 800
His Arg Asp Ile Lys Gly Asp Asn Val Leu Ile Asn Thr Tyr Ser Gly
805 810 815
Val Leu Lys Ile Ser Asp Phe Gly Thr Ser Lys Arg Leu Ala Gly Ile
820 825 830
Asn Pro Cys Thr Glu Thr Phe Thr Gly Thr Leu Gln Tyr Met Ala Pro
835 840 845
Glu Ile Ile Asp Lys Gly Pro Arg Gly Tyr Gly Lys Ala Ala Asp Ile
850 855 860
Trp Ser Leu Gly Cys Thr Ile Ile Glu Met Ala Thr Gly Lys Pro Pro
865 870 875 880
Phe Tyr Glu Leu Gly Glu Pro Gln Ala Ala Met Phe Lys Val Gly Met
885 890 895
Phe Lys Val His Pro Glu Ile Pro Glu Ser Met Ser Ala Glu Ala Lys
900 905 910
Ala Phe Ile Leu Lys Cys Phe Glu Pro Asp Pro Asp Lys Arg Ala Cys
915 920 925
Ala Asn Asp Leu Leu Val Asp Glu Phe Leu Lys Val Ser Ser Lys Lys
930 935 940
Lys Lys Thr Gln Pro Lys Leu Ser Ala Leu Ser Ala Gly Ser Asn Glu
945 950 955 960
Tyr Leu Arg Ser Ile Ser Leu Pro Val Pro Val Leu Val Glu Asp Thr
965 970 975
Ser Ser Ser Ser Glu Tyr Gly Ser Val Ser Pro Asp Thr Glu Leu Lys
980 985 990
Val Asp Pro Phe Ser Phe Lys Thr Arg Ala Lys Ser Cys Gly Glu Arg
995 1000 1005
Asp Val Lys Gly Ile Arg Thr Leu Phe Leu Gly Ile Pro Asp Glu Asn
1010 1015 1020
Phe Glu Asp His Ser Ala Pro Pro Ser Pro Glu Glu Lys Asp Ser Gly
1025 1030 1035 1040
Phe Phe Met Leu Arg Lys Asp Ser Glu Arg Arg Ala Thr Leu His Arg
1045 1050 1055
Ile Leu Thr Glu Asp Gln Asp Lys Ile Val Arg Asn Leu Met Glu Ser
1060 1065 1070
Leu Ala Gln Gly Ala Glu Glu Pro Lys Leu Lys Trp Glu His Ile Thr
1075 1080 1085
Thr Leu Ile Ala Ser Leu Arg Glu Phe Val Arg Ser Thr Asp Arg Lys
1090 1095 1100
Ile Ile Ala Thr Thr Leu Ser Lys Leu Lys Leu Glu Leu Asp Phe Asp
1105 1110 1115 1120
Ser His Gly Ile Ser Gln Val Gln Val Val Leu Phe Gly Phe Gln Asp
1125 1130 1135
Ala Val Asn Lys Val Leu Arg Asn His Asn Ile Lys Pro His Trp Met
1140 1145 1150
Phe Ala Leu Asp Ser Ile Ile Arg Lys Ala Val Gln Thr Ala Ile Thr
1155 1160 1165
Ile Leu Val Pro Glu Leu Arg Pro His Phe Ser Leu Ala Ser Glu Ser
1170 1175 1180
Asp Thr Ala Asp Gln Glu Asp Leu Asp Val Glu Asp Asp His Glu Glu
1185 1190 1195 1200
Gln Pro Ser Asn Gln Thr Val Arg Arg Pro Gln Ala Val Ile Glu Asp
1205 1210 1215
Ala Val Ala Thr Ser Gly Val Ser Thr Leu Ser Ser Thr Val Ser His
1220 1225 1230
Asp Ser Gln Ser Ala His Arg Ser Leu Asn Val Gln Leu Gly Arg Met
1235 1240 1245
Lys Ile Glu Thr Asn Arg Leu Leu Glu Glu Leu Val Arg Lys Glu Lys
1250 1255 1260
Glu Leu Gln Ala Leu Leu His Arg Ala Ile Glu Glu Lys Asp Gln Glu
1265 1270 1275 1280
Ile Lys His Leu Lys Leu Lys Ser Gln Pro Ile Glu Ile Pro Glu Leu
1285 1290 1295
Pro Val Phe His Leu Asn Ser Ser Gly Thr Asn Thr Glu Asp Ser Glu
1300 1305 1310
Leu Thr Asp Trp Leu Arg Val Asn Gly Ala Asp Glu Asp Thr Ile Ser
1315 1320 1325
Arg Phe Leu Ala Glu Asp Tyr Thr Leu Leu Asp Val Leu Tyr Tyr Val
1330 1335 1340
Thr Arg Asp Asp Leu Lys Cys Leu Arg Leu Arg Gly Gly Met Leu Cys
1345 1350 1355 1360
Thr Leu Trp Lys Ala Ile Ile Asp Phe Arg Asn Lys Gln Thr
1365 1370
<210> 3
<211> 248
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Met Ala Gly Ile Thr Thr Ile Glu Ala Val Lys Arg Lys Ile Gln Val
1 5 10 15
Leu Gln Gln Gln Ala Asp Asp Ala Glu Glu Arg Ala Glu Arg Leu Gln
20 25 30
Arg Glu Val Glu Gly Glu Arg Arg Ala Arg Glu Gln Ala Glu Ala Glu
35 40 45
Val Ala Ser Leu Asn Arg Arg Ile Gln Leu Val Glu Glu Glu Leu Asp
50 55 60
Arg Ala Gln Glu Arg Leu Ala Thr Ala Leu Gln Lys Leu Glu Glu Ala
65 70 75 80
Glu Lys Ala Ala Asp Glu Ser Glu Arg Gly Met Lys Val Ile Glu Asn
85 90 95
Arg Ala Leu Lys Asp Glu Glu Lys Met Glu Leu Gln Glu Ile Gln Leu
100 105 110
Lys Glu Ala Lys His Ile Ala Glu Glu Ala Asp Arg Lys Tyr Glu Glu
115 120 125
Val Ala Arg Lys Leu Val Ile Ile Glu Gly Asp Leu Glu Arg Thr Glu
130 135 140
Glu Arg Ala Glu Leu Ala Glu Ser Lys Cys Ser Glu Leu Glu Glu Glu
145 150 155 160
Leu Lys Asn Val Thr Asn Asn Leu Lys Ser Leu Glu Ala Gln Ala Glu
165 170 175
Lys Tyr Ser Gln Lys Glu Asp Lys Tyr Glu Glu Glu Ile Lys Ile Leu
180 185 190
Thr Asp Lys Leu Lys Glu Ala Glu Thr Arg Ala Glu Phe Ala Glu Arg
195 200 205
Ser Val Ala Lys Leu Glu Lys Thr Ile Asp Asp Leu Glu Asp Lys Leu
210 215 220
Lys Cys Thr Lys Glu Glu His Leu Cys Thr Gln Arg Met Leu Asp Gln
225 230 235 240
Thr Leu Leu Asp Leu Asn Glu Met
245
<210> 4
<211> 166
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Met Ala Ser Gly Val Ala Val Ser Asp Gly Val Ile Lys Val Phe Asn
1 5 10 15
Asp Met Lys Val Arg Lys Ser Ser Thr Pro Glu Glu Val Lys Lys Arg
20 25 30
Lys Lys Ala Val Leu Phe Cys Leu Ser Glu Asp Lys Lys Asn Ile Ile
35 40 45
Leu Glu Glu Gly Lys Glu Ile Leu Val Gly Asp Val Gly Gln Thr Val
50 55 60
Asp Asp Pro Tyr Ala Thr Phe Val Lys Met Leu Pro Asp Lys Asp Cys
65 70 75 80
Arg Tyr Ala Leu Tyr Asp Ala Thr Tyr Glu Thr Lys Glu Ser Lys Lys
85 90 95
Glu Asp Leu Val Phe Ile Phe Trp Ala Pro Glu Ser Ala Pro Leu Lys
100 105 110
Ser Lys Met Ile Tyr Ala Ser Ser Lys Asp Ala Ile Lys Lys Lys Leu
115 120 125
Thr Gly Ile Lys His Glu Leu Gln Ala Asn Cys Tyr Glu Glu Val Lys
130 135 140
Asp Arg Cys Thr Leu Ala Glu Lys Leu Gly Gly Ser Ala Val Ile Ser
145 150 155 160
Leu Glu Gly Lys Pro Leu
165
<210> 5
<211> 634
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Met Ala His Tyr Asn Phe Lys Lys Ile Thr Val Val Pro Ser Ala Lys
1 5 10 15
Asp Phe Ile Asp Leu Thr Leu Ser Lys Thr Gln Arg Lys Thr Pro Thr
20 25 30
Val Ile His Lys His Tyr Gln Ile His Arg Ile Arg His Phe Tyr Met
35 40 45
Arg Lys Val Lys Phe Thr Gln Gln Asn Tyr His Asp Arg Leu Ser Gln
50 55 60
Ile Leu Thr Asp Phe Pro Lys Leu Asp Asp Ile His Pro Phe Tyr Ala
65 70 75 80
Asp Leu Met Asn Ile Leu Tyr Asp Lys Asp His Tyr Lys Leu Ala Leu
85 90 95
Gly Gln Ile Asn Ile Ala Lys Asn Leu Val Asp Asn Val Ala Lys Asp
100 105 110
Tyr Val Arg Leu Met Lys Tyr Gly Asp Ser Leu Tyr Arg Cys Lys Gln
115 120 125
Leu Lys Arg Ala Ala Leu Gly Arg Met Cys Thr Val Ile Lys Arg Gln
130 135 140
Lys Gln Ser Leu Glu Tyr Leu Glu Gln Val Arg Gln His Leu Ser Arg
145 150 155 160
Leu Pro Thr Ile Asp Pro Asn Thr Arg Thr Leu Leu Leu Cys Gly Tyr
165 170 175
Pro Asn Val Gly Lys Ser Ser Phe Ile Asn Lys Val Thr Arg Ala Asp
180 185 190
Val Asp Val Gln Pro Tyr Ala Phe Thr Thr Lys Ser Leu Phe Val Gly
195 200 205
His Met Asp Tyr Lys Tyr Leu Arg Trp Gln Val Val Asp Thr Pro Gly
210 215 220
Ile Leu Asp His Pro Leu Glu Asp Arg Asn Thr Ile Glu Met Gln Ala
225 230 235 240
Ile Thr Ala Leu Ala His Leu Arg Ala Ala Val Leu Tyr Val Met Asp
245 250 255
Leu Ser Glu Gln Cys Gly His Gly Leu Arg Glu Gln Leu Glu Leu Phe
260 265 270
Gln Asn Ile Arg Pro Leu Phe Ile Asn Lys Pro Leu Ile Val Val Ala
275 280 285
Asn Lys Cys Asp Val Lys Arg Ile Ala Glu Leu Ser Glu Asp Asp Gln
290 295 300
Lys Ile Phe Thr Asp Leu Gln Ser Glu Gly Phe Pro Val Ile Glu Thr
305 310 315 320
Ser Thr Leu Thr Glu Glu Gly Val Ile Lys Val Lys Thr Glu Ala Cys
325 330 335
Asp Arg Leu Leu Ala His Arg Val Glu Thr Lys Met Lys Gly Asn Lys
340 345 350
Val Asn Glu Val Leu Asn Arg Leu His Leu Ala Ile Pro Thr Arg Arg
355 360 365
Asp Asp Lys Glu Arg Pro Pro Phe Ile Pro Glu Gly Val Val Ala Arg
370 375 380
Arg Lys Arg Met Glu Thr Glu Glu Ser Arg Lys Lys Arg Glu Arg Asp
385 390 395 400
Leu Glu Leu Glu Met Gly Asp Asp Tyr Ile Leu Asp Leu Gln Lys Tyr
405 410 415
Trp Asp Leu Met Asn Leu Ser Glu Lys His Asp Lys Ile Pro Glu Ile
420 425 430
Trp Glu Gly His Asn Ile Ala Asp Tyr Ile Asp Pro Ala Ile Met Lys
435 440 445
Lys Leu Glu Glu Leu Glu Lys Glu Glu Glu Leu Arg Thr Ala Ala Gly
450 455 460
Glu Tyr Asp Ser Val Ser Glu Ser Glu Asp Glu Glu Met Leu Glu Ile
465 470 475 480
Arg Gln Leu Ala Lys Gln Ile Arg Glu Lys Lys Lys Leu Lys Ile Leu
485 490 495
Glu Ser Lys Glu Lys Asn Thr Gln Gly Pro Arg Met Pro Arg Thr Ala
500 505 510
Lys Lys Val Gln Arg Thr Val Leu Glu Lys Glu Met Arg Ser Leu Gly
515 520 525
Val Asp Met Asp Asp Lys Asp Asp Ala His Tyr Ala Val Gln Ala Arg
530 535 540
Arg Ser Arg Ser Ile Thr Arg Lys Arg Lys Arg Glu Asp Ser Ala Pro
545 550 555 560
Pro Ser Ser Val Ala Arg Ser Gly Ser Cys Ser Arg Thr Pro Arg Asp
565 570 575
Val Ser Gly Leu Arg Asp Val Lys Met Val Lys Lys Ala Lys Thr Met
580 585 590
Met Lys Asn Ala Gln Lys Lys Met Asn Arg Leu Gly Lys Lys Gly Glu
595 600 605
Ala Asp Arg His Val Phe Asp Met Lys Pro Lys His Leu Leu Ser Gly
610 615 620
Lys Arg Lys Ala Gly Lys Lys Asp Arg Arg
625 630
<210> 6
<211> 199
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Met Pro Glu Gln Ser Asn Asp Tyr Arg Val Ala Val Phe Gly Ala Gly
1 5 10 15
Gly Val Gly Lys Ser Ser Leu Val Leu Arg Phe Val Lys Gly Thr Phe
20 25 30
Arg Glu Ser Tyr Ile Pro Thr Val Glu Asp Thr Tyr Arg Gln Val Ile
35 40 45
Ser Cys Asp Lys Ser Ile Cys Thr Leu Gln Ile Thr Asp Thr Thr Gly
50 55 60
Ser His Gln Phe Pro Ala Met Gln Arg Leu Ser Ile Ser Lys Gly His
65 70 75 80
Ala Phe Ile Leu Val Tyr Ser Ile Thr Ser Arg Gln Ser Leu Glu Glu
85 90 95
Leu Lys Pro Ile Tyr Glu Gln Ile Cys Glu Ile Lys Gly Asp Val Glu
100 105 110
Ser Ile Pro Ile Met Leu Val Gly Asn Lys Cys Asp Glu Ser Pro Ser
115 120 125
Arg Glu Val Gln Ser Ser Glu Ala Glu Ala Leu Ala Arg Thr Trp Lys
130 135 140
Cys Ala Phe Met Glu Thr Ser Ala Lys Leu Asn His Asn Val Lys Glu
145 150 155 160
Leu Phe Gln Glu Leu Leu Asn Leu Glu Lys Arg Arg Thr Val Ser Leu
165 170 175
Gln Ile Asp Gly Lys Lys Ser Lys Gln Gln Lys Arg Lys Glu Lys Leu
180 185 190
Lys Gly Lys Cys Val Ile Met
195
<210> 7
<211> 589
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Met Ala Ala Ala Asp Gly Asp Asp Ser Leu Tyr Pro Ile Ala Val Leu
1 5 10 15
Ile Asp Glu Leu Arg Asn Glu Asp Val Gln Leu Arg Leu Asn Ser Ile
20 25 30
Lys Lys Leu Ser Thr Ile Ala Leu Ala Leu Gly Val Glu Arg Thr Arg
35 40 45
Ser Glu Leu Leu Pro Phe Leu Thr Asp Thr Ile Tyr Asp Glu Asp Glu
50 55 60
Val Leu Leu Ala Leu Ala Glu Gln Leu Gly Thr Phe Thr Thr Leu Val
65 70 75 80
Gly Gly Pro Glu Tyr Val His Cys Leu Leu Pro Pro Leu Glu Ser Leu
85 90 95
Ala Thr Val Glu Glu Thr Val Val Arg Asp Lys Ala Val Glu Ser Leu
100 105 110
Arg Ala Ile Ser His Glu His Ser Pro Ser Asp Leu Glu Ala His Phe
115 120 125
Val Pro Leu Val Lys Arg Leu Ala Gly Gly Asp Trp Phe Thr Ser Arg
130 135 140
Thr Ser Ala Cys Gly Leu Phe Ser Val Cys Tyr Pro Arg Val Ser Ser
145 150 155 160
Ala Val Lys Ala Glu Leu Arg Gln Tyr Phe Arg Asn Leu Cys Ser Asp
165 170 175
Asp Thr Pro Met Val Arg Arg Ala Ala Ala Ser Lys Leu Gly Glu Phe
180 185 190
Ala Lys Val Leu Glu Leu Asp Asn Val Lys Ser Glu Ile Ile Pro Met
195 200 205
Phe Ser Asn Leu Ala Ser Asp Glu Gln Asp Ser Val Arg Leu Leu Ala
210 215 220
Val Glu Ala Cys Val Asn Ile Ala Gln Leu Leu Pro Gln Glu Asp Leu
225 230 235 240
Glu Ala Leu Val Met Pro Thr Leu Arg Gln Ala Ala Glu Asp Lys Ser
245 250 255
Trp Arg Val Arg Tyr Met Val Ala Asp Lys Phe Thr Glu Leu Gln Lys
260 265 270
Ala Val Gly Pro Glu Ile Thr Lys Thr Asp Leu Val Pro Ala Phe Gln
275 280 285
Asn Leu Met Lys Asp Cys Glu Ala Glu Val Arg Ala Ala Ala Ser His
290 295 300
Lys Val Lys Glu Phe Cys Glu Asn Leu Ser Ala Asp Cys Arg Glu Asn
305 310 315 320
Val Ile Met Ser Gln Ile Leu Pro Cys Ile Lys Glu Leu Val Ser Asp
325 330 335
Ala Asn Gln His Val Lys Ser Ala Leu Ala Ser Val Ile Met Gly Leu
340 345 350
Ser Pro Ile Leu Gly Lys Asp Asn Thr Ile Glu His Leu Leu Pro Leu
355 360 365
Phe Leu Ala Gln Leu Lys Asp Glu Cys Pro Glu Val Arg Leu Asn Ile
370 375 380
Ile Ser Asn Leu Asp Cys Val Asn Glu Val Ile Gly Ile Arg Gln Leu
385 390 395 400
Ser Gln Ser Leu Leu Pro Ala Ile Val Glu Leu Ala Glu Asp Ala Lys
405 410 415
Trp Arg Val Arg Leu Ala Ile Ile Glu Tyr Met Pro Leu Leu Ala Gly
420 425 430
Gln Leu Gly Val Glu Phe Phe Asp Glu Lys Leu Asn Ser Leu Cys Met
435 440 445
Ala Trp Leu Val Asp His Val Tyr Ala Ile Arg Glu Ala Ala Thr Ser
450 455 460
Asn Leu Lys Lys Leu Val Glu Lys Phe Gly Lys Glu Trp Ala His Ala
465 470 475 480
Thr Ile Ile Pro Lys Val Leu Ala Met Ser Gly Asp Pro Asn Tyr Leu
485 490 495
His Arg Met Thr Thr Leu Phe Cys Ile Asn Val Leu Ser Glu Val Cys
500 505 510
Gly Gln Asp Ile Thr Thr Lys His Met Leu Pro Thr Val Leu Arg Met
515 520 525
Ala Gly Asp Pro Val Ala Asn Val Arg Phe Asn Val Ala Lys Ser Leu
530 535 540
Gln Lys Ile Gly Pro Ile Leu Asp Asn Ser Thr Leu Gln Ser Glu Val
545 550 555 560
Lys Pro Ile Leu Glu Lys Leu Thr Gln Asp Gln Asp Val Asp Val Lys
565 570 575
Tyr Phe Ala Gln Glu Ala Leu Thr Val Leu Ser Leu Ala
580 585
<210> 8
<211> 886
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 8
ctcgcaggct ccaggggcgg ggcgtggccg gggcgcagcg acgggcgcgg aggtccggcc 60
gggcgcgcgc gcccccgcca cacgcacgcc gggcgtgcca gtttataaag ggagagagca 120
agcagcgagt cttgaagctc tgtttggtgc tttggatcca tttccatcgg tccttacagc 180
cgctcgtcag actccagcag ccaagatggt gaagcagatc gagagcaaga ctgcttttca 240
ggaagccttg gacgctgcag gtgataaact tgtagtagtt gacttctcag ccacgtggtg 300
tgggccttgc aaaatgatca agcctttctt tcattccctc tctgaaaagt attccaacgt 360
gatattcctt gaagtagatg tggatgactg tcaggatgtt gcttcagagt gtgaagtcaa 420
atgcatgcca acattccagt tttttaagaa gggacaaaag gtgggtgaat tttctggagc 480
caataaggaa aagcttgaag ccaccattaa tgaattagtc taatcatgtt ttctgaaaat 540
ataaccagcc attggctatt taaaacttgt aattttttta atttacaaaa atataaaata 600
tgaagacata aacccagttg ccatctgcgt gacaataaaa cattaatgct aacacttttt 660
aaaaccgtct catgtctgaa tagctttcaa aataaatgtg aaatggtcat ttaatgtatt 720
ttcctatatt ctcaatcact ttttagtaac cttgtaggcc actgattatt ttaagatttt 780
aaaaattatt attgctacct taatgtattg ctacaaaaat ctcttgttgg gggcaatgca 840
ggtaataaag tagtatgttg ttatttgtaa aaaaaaaaaa aaaaaa 886
<210> 9
<211> 5215
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
cgagcgcggc gcccttgagc tgcaccgcgg cgcaggtttg cgagccgact tgtcagccgg 60
ccaagaaaag gaagctccgt cccttcccgc tcacccggct tccccacccc ttgtactcta 120
aactctgcag agggcgagcg gcgcggccac ggaggcgccg aggaggagcg agccgccgcc 180
gggcagcggc gtgccctcgg gggagagggc gccggagagg aggcggcggc gcggcggcga 240
gggcgcggcg cgcgatggca gctgcttagc ccggcgggcg cggagcagcc ccgagctgtg 300
gctggccagg cggtgcggct gggcggggga cgccgccgcc gttgctgccc ggcccggaga 360
gatgagcacg gaggcggacg agggcatcac tttctctgtg ccacccttcg ccccctcggg 420
cttctgcacc atccccgagg gcggcatctg caggagggga ggagcggcgg cggtgggcga 480
gggcgaggag caccagctgc caccgccgcc gccgggcagc ttctggaacg tggagagcgc 540
cgctgcccct ggcatcggtt gtccggcggc cacctcctcg agcagtgcca cccgaggccg 600
gggcagctct gttggcgggg gcagccgacg gaccacggtg gcatatgtga tcaacgaagc 660
gagccaaggg caactggtgg tggccgagag cgaggccctg cagagcttgc gggaggcgtg 720
cgagacagtg ggcgccaccc tggaaaccct gcattttggg aaactcgact ttggagaaac 780
caccgtgctg gaccgctttt acaatgcaga tattgcggtg gtggagatga gcgatgcctt 840
ccggcagccg tccttgtttt accaccttgg ggtgagagaa agtttcagca tggccaacaa 900
catcatcctc tactgtgata ctaactcgga ctctctgcag tcactgaagg aaataatttg 960
ccagaagaat actatgtgca ctgggaacta cacctttgtt ccttacatga taactccaca 1020
taacaaagtc tactgctgtg acagcagctt catgaagggg ttgacagagc tcatgcaacc 1080
gaacttcgag ctgcttcttg gacccatctg cttacctctt gtggatcgtt ttattcaact 1140
tttgaaggtg gcacaagcaa gttctagcca gtacttccgg gaatctatac tcaatgacat 1200
caggaaagct cgtaatttat acactggtaa agaattggca gctgagttgg caagaattcg 1260
gcagcgagta gataatatcg aagtcttgac agcagatatt gtcataaatc tgttactttc 1320
ctacagagat atccaggact atgattctat tgtgaagctg gtagagactt tagaaaaact 1380
gccaaccttt gatttggcct cccatcacca tgtgaagttt cattatgcat ttgcactgaa 1440
taggagaaat ctccctggtg acagagcaaa agctcttgat attatgattc ccatggtgca 1500
aagcgaagga caagttgctt cagatatgta ttgcctagtt ggtcgaatct acaaagatat 1560
gtttttggac tctaatttca cggacactga aagcagagac catggagctt cttggttcaa 1620
aaaggcattt gaatctgagc caacactaca gtcaggaatt aattatgcgg tcctcctcct 1680
ggcagctgga caccagtttg aatcttcctt tgagctccgg aaagttgggg tgaagctaag 1740
tagtcttctt ggtaaaaagg gaaacttgga aaaactccag agctactggg aagttggatt 1800
ttttctgggg gccagcgtcc tagccaatga ccacatgaga gtcattcaag catctgaaaa 1860
gctttttaaa ctgaagacac cagcatggta cctcaagtct attgtagaga caattttaat 1920
atataagcat tttgtgaaac tgaccacaga acagcctgtg gccaagcaag aacttgtgga 1980
cttttggatg gatttcctgg tcgaggccac aaagacagat gttactgtgg ttaggtttcc 2040
agtattaata ttagaaccaa ccaaaatcta tcaaccttct tatttgtcta tcaacaatga 2100
agttgaggaa aagacaatct ctatttggca cgtgcttcct gatgacaaga aaggtataca 2160
tgagtggaat tttagtgcct cttctgtcag gggagtgagt atttctaaat ttgaagaaag 2220
atgctgcttt ctttatgtgc ttcacaattc tgatgatttc caaatctatt tctgtacaga 2280
acttcattgt aaaaagtttt ttgagatggt gaacaccatt accgaagaga aggggagaag 2340
cacagaggaa ggagactgtg aaagtgactt gctggagtat gactatgaat atgatgaaaa 2400
tggtgacaga gtcgttttag gaaaaggcac ttatgggata gtctacgcag gtcgggactt 2460
gagcaaccaa gtcagaattg ctattaagga aatcccagag agagacagca gatactctca 2520
gcccctgcat gaagaaatag cattgcataa acacctgaag cacaaaaata ttgtccagta 2580
tctgggctct ttcagtgaga atggtttcat taaaatcttc atggagcagg tccctggagg 2640
aagtctttct gctctccttc gttccaaatg gggtccatta aaagacaatg agcaaacaat 2700
tggcttttat acaaagcaaa tactggaagg attaaaatat ctccatgaca atcagatagt 2760
tcaccgggac ataaagggtg acaatgtgtt gattaatacc tacagtggtg ttctcaagat 2820
ctctgacttc ggaacatcaa agaggcttgc tggcataaac ccctgtactg aaacttttac 2880
tggtaccctc cagtatatgg caccagaaat aatagataaa ggaccaagag gctacggaaa 2940
agcagcagac atctggtctc tgggctgtac aatcattgaa atggccacag gaaaaccccc 3000
attttatgaa ctgggagaac cacaagcagc tatgttcaag gtgggaatgt ttaaagtcca 3060
ccctgagatc ccagagtcca tgtctgcaga ggccaaggca ttcatactga aatgttttga 3120
accagatcct gacaagagag cctgtgctaa cgacttgctt gttgatgagt ttttaaaagt 3180
ttcaagcaaa aagaaaaaga cacaacctaa gctttcagct ctttcagctg gatcaaatga 3240
atatctcagg agtatatcct tgccggtacc tgtgctggtg gaggacacca gcagcagcag 3300
tgagtacggc tcagtttcac ccgacacgga gttgaaagtg gaccccttct ctttcaaaac 3360
aagagccaag tcctgcggag aaagagatgt caagggaatt cggacactct ttttgggcat 3420
tccagatgag aattttgaag atcacagtgc tcctccttcc cctgaagaaa aagattctgg 3480
attcttcatg ctgaggaagg acagtgagag gcgagctacc cttcacagga tcctgacgga 3540
agaccaagac aaaattgtga gaaacctaat ggaatcttta gctcaggggg ctgaagaacc 3600
gaaactaaaa tgggaacaca tcacaaccct cattgcaagc ctcagagaat ttgtgagatc 3660
cactgaccga aaaatcatag ccaccacact gtcaaagctg aaactggagc tggacttcga 3720
cagccatggc attagccaag tccaggtggt actctttggt tttcaagatg ctgtcaataa 3780
agttcttcgg aatcataaca tcaagccgca ctggatgttt gccttagaca gtatcattcg 3840
gaaggcggta cagacagcca ttaccatcct ggttccagaa ctaaggccac atttcagcct 3900
tgcatctgag agtgatactg ctgatcaaga agacttggat gtagaagatg accatgagga 3960
acagccttca aatcaaactg tccgaagacc tcaggctgtc attgaagatg ctgtggctac 4020
ctcaggcgtg agcacgctca gttctactgt gtctcatgat tcccagagtg ctcaccggtc 4080
actgaatgta cagcttggaa ggatgaaaat agaaaccaat agattactgg aagaattggt 4140
tcggaaagag aaagaattac aagcactcct tcatcgagct attgaagaaa aagaccaaga 4200
aattaaacac ctgaagctta agtcccaacc catagaaatt cctgaattgc ctgtatttca 4260
tctaaattct tctggcacaa atactgaaga ttctgaactt accgactggc tgagagtgaa 4320
tggagctgat gaagacacta taagccggtt tttggctgaa gattatacac tattggatgt 4380
tctctactat gttacacgtg atgacttaaa atgcttgaga ctaaggggag ggatgctgtg 4440
cacactgtgg aaggctatca ttgactttcg aaacaaacag acttgactgt tgctcaatct 4500
aatcttcgat ggaaattcta aaaattaata cagagctgat cttcttgggg gtgggaaaat 4560
cgaagggaga ggagaaaggc gctgcacttt aaatccagta tttgtttact catgttaaaa 4620
aaaaaaaaaa cagacaaaac acactgaaat ttcctaacta catctatttc tataattttt 4680
aaggactctt cataaggact cttaaaataa tcctgaacat tagaacccta atgttcagga 4740
agattttaat ctaagcattt ttatggaaat atttttaatg cagcagctat tgcacttcag 4800
ccaaatgttt atttcacaca aaacggatgt aacatttcat gtgatcgtgc accactggaa 4860
caaaaccaaa atgtgaccat aactgtttag gcttctgtgt gtttgtaata tgctctaata 4920
atctgagtag aaatgcgtaa tttcaattac tgtataaagt ttatgttttt ttaagtgtgc 4980
agaatctgag agcaatggtt tttacttctc tgtgttaatt gtaatattga ctctattttg 5040
taacttaagt ttctgacctg tcgtacattt gtttgagtcg tttatgtact actgaactgt 5100
accagttgca catgcttgaa ctgtagtaat gttagcttgt tctaaagcta tccattgtgt 5160
catatttact ctaaaaatta aagagactct caacaaaaaa aaaaaaaaaa aaaaa 5215
<210> 10
<211> 3212
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
gtcacatccg ggcgggttgg tgagttccgg tatttcaggg cgtagcaggc ggaagtaagg 60
gtgagaggag gctgcaacgc cgagcggagg aggcaggaac cggagcgcga gcagtagctg 120
ggtgggcacc atggctggga tcaccaccat cgaggcggtg aagcgcaaga tccaggttct 180
gcagcagcag gcagatgatg cagaggagcg agctgagcgc ctccagcgag aagttgaggg 240
agaaaggcgg gcccgggaac aggctgaggc tgaggtggcc tccttgaacc gtaggatcca 300
gctggttgaa gaagagctgg accgtgctca ggagcgcctg gccactgccc tgcaaaagct 360
ggaagaagct gaaaaagctg ctgatgagag tgagagaggt atgaaggtta ttgaaaaccg 420
ggccttaaaa gatgaagaaa agatggaact ccaggaaatc caactcaaag aagctaagca 480
cattgcagaa gaggcagata ggaagtatga agaggtggct cgtaagttgg tgatcattga 540
aggagacttg gaacgcacag aggaacgagc tgagctggca gagtctaagt gttctgagct 600
ggaggaggag ctgaagaatg tcaccaacaa cctcaagtct cttgaggctc aggcggagaa 660
gtactctcaa aaagaagata aatatgagga agaaatcaag attcttactg ataaactcaa 720
ggaggcagag acccgtgctg agtttgctga gagatcggta gccaagctgg aaaagacaat 780
tgatgacctg gaagataaac tgaaatgcac caaagaggag cacctctgta cacaaaggat 840
gctggaccag accctgcttg acctgaatga gatgtagaac gccccagtcc caccctgctg 900
ctgctcctcc ctctgaccca gactccgcct gaggccagcc tgcgggaagc tgacctttaa 960
ctgagggctg atctttaact ggaaggctgc tttctccttt caccaccccc tccttccctg 1020
tgtctttttc gccaaactgt ctctgcctct tcccggagaa tccagctggg ctagaggctg 1080
agcacctttg gaaacaacat ttaagggaat gtgagcacaa tgcataatgt ctttaaaaag 1140
catgttgtga tgtacacatt ttgtaattac cttttttgtt gttttgtagc aaccatttgt 1200
aaaacattcc aaataattcc acagtcctga agcagcaatc gaatcccttt ctcacttttg 1260
gaaggtgact tttcacctta atgcatattc ccctctccat agaggagagg aaaaggtgta 1320
ggcctgcctt accgagagcc aaacagagcc cagggagact ccgctgtggg aaacctcatt 1380
gttctgtaca aagtactagc taaaccagaa aggtgattcc aggaggagtt agccaaacaa 1440
caacaaaaac aaaaaatgtg ctgttcaagt tttcagcttt aagatatctt tggataatgt 1500
tatttctatt ttttattttt ttcattagaa gttaccaaat taagatggta agacctctga 1560
gaccaaaatt ttgtcccatc tctaccccct cacaactgct tacagaatgg atcatgtccc 1620
ccttatgttg aggtgaccac ttaattgctt tcctgcctcc ttgaaagaaa gaaagaaaga 1680
agactgtgtt tttgccactg atttagccat gtgaaactca tctcattacc cttttctggg 1740
tttgaagctg ctgtctctag aagtgccatc tcaattgtgc tttgtatcag tcagtgctgg 1800
agaaatcttg aatagcttat gtacaaaact ttttaaattt tatattattt tgaaactttg 1860
ctttgggttt gtggcaccct ggccacccca tctggctgtg acagcctctg cagtccgtgg 1920
gctggcagtt tgttgatctt ttaagtttcc ttccctaccc agtccccatt ttctggtaag 1980
gtttctagga ggtctgttag gtgtacatcc tgcagcttat tggcttaaaa tgtactctcc 2040
ttttatgtgg tctctttggg gccgattggg agaaagagaa atcaatagtg caactgtttt 2100
gatactgaat attgacaagt gtctttttga aataaagaac cagtccctcc aaccctcaga 2160
cctatttgac ttttatttat taaaactaaa tgtgctttct ccacagaagc tatgaggttt 2220
gggttaaaaa tagcatcttt gtgggtggta gcaacaggat ttattcttta ttattattat 2280
ttttgagatg aagtttcatt cttgttgcct gggctggagc gtaatggctc gatctcggct 2340
cactgcaacc tccgcctcct ggttcaagag attctcctgc ctcagcctcc cgagtagctg 2400
ggattacagg cacctgccac catgcccggg taatttttta tattttaagt agagacaggg 2460
cttcaccatg ttggccaggc tggtctcgaa ctcctgacct tcaggtgatc cacctgcctc 2520
agcttcccaa aatgctggga ttacgggcgt gagccaccgc acccagctgg agcaacagga 2580
tttaatatag agcaaatgtt tagttttatc atctgtaaaa tggagataag tattgtcaga 2640
gtaaacatga agattagaaa gaacacttaa tgtgctgggc cttttatagg ttaacactga 2700
catctcaggc tgaactatat acattttcct tcacaaccat atcaatcctt ataaactatg 2760
gatttatgct ccttaaaaca atatataatg ctgatcacta ctataaatgc gtggttttaa 2820
ccaactgtac tgaaacagct ttgagtttat attctgtttg gatatttgga gaaaacaaca 2880
agtgctctca agagtatttg cttagaggcc ggctgtgtga gtggataact ttgaaagctg 2940
cttttgagac gccagtgtct ggcatttcct gcattctggc ctggaggccg gacgtgaatc 3000
tgacttctag taaaaataca cggttccctt gacaaagtcg agctgtttat cccagagact 3060
gcacaatttt ccgttgatag gcatggacca atgctaactg gaaatcattg caaaaagttt 3120
ttttgtcggg cggagggtgt ggtgttaaga taaacagtgt gcaacagaag aaattaaaac 3180
tggaagaaat taaagggttt tttttagact tt 3212
<210> 11
<211> 1260
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 11
ggccggcggg aagactccgt tacccagcga gcgaggcggc ggcgcagggc cagcggactc 60
catttcccgt cggctcgcgg tgggagcgcc ggaagcccgc cccacccctc attgtgcggc 120
tcctactaaa cggaaggggc cgggagaggc cgcgttcagt cgggtcccgg cagcggctgc 180
agcgctctcg tcttctgcgg ctctcggtgc cctctccttt tcgtttccgg aaacatggcc 240
tccggtgtgg ctgtctctga tggtgtcatc aaggtgttca acgacatgaa ggtgcgtaag 300
tcttcaacgc cagaggaggt gaagaagcgc aagaaggcgg tgctcttctg cctgagtgag 360
gacaagaaga acatcatcct ggaggagggc aaggagatcc tggtgggcga tgtgggccag 420
actgtcgacg acccctacgc cacctttgtc aagatgctgc cagataagga ctgccgctat 480
gccctctatg atgcaaccta tgagaccaag gagagcaaga aggaggatct ggtgtttatc 540
ttctgggccc ccgagtctgc gccccttaag agcaaaatga tttatgccag ctccaaggac 600
gccatcaaga agaagctgac agggatcaag catgaattgc aagcaaactg ctacgaggag 660
gtcaaggacc gctgcaccct ggcagagaag ctggggggca gtgccgtcat ctccctggag 720
ggcaagcctt tgtgagcccc ttctggcccc ctgcctggag catctggcag ccccacacct 780
gcccttgggg gttgcaggct gcccccttcc tgccagaccg gaggggctgg ggggatccca 840
gcagggggag ggcaatccct tcaccccagt tgccaaacag accccccacc ccctggattt 900
tccttctccc tccatccctt gacggttctg gccttcccaa actgcttttg atcttttgat 960
tcctcttggg ctgaagcaga ccaagttccc cccaggcacc ccagttgtgg gggagcctgt 1020
atttttttta acaacatccc cattccccac ctggtcctcc cccttcccat gctgccaact 1080
tctaaccgca atagtgactc tgtgcttgtc tgtttagttc tgtgtataaa tggaatgttg 1140
tggagatgac ccctccctgt gccggctggt tcctctccct tttcccctgg tcacggctac 1200
tcatggaagc aggaccagta agggaccttc gattaaaaaa aaaaaagaca ataataaaaa 1260
<210> 12
<211> 2537
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 12
ggaagtccca cctgcgcccg acggcggaag ttccgggagt gccaagtacc cgcgtgcata 60
cggctgccgg catggcacat tacaacttca agaaaattac ggtggtgccg tccgccaagg 120
acttcataga cctcacgttg tcgaagactc aacgaaagac tccaaccgtt attcataaac 180
attaccaaat acatcgcatt agacattttt acatgagaaa agtcaaattt actcaacaga 240
attaccatga tagactttca caaattctaa cagatttccc caaattggat gatattcatc 300
cgttctatgc tgatttgatg aatattctct acgacaagga tcattacaag ttggctctgg 360
ggcaaataaa tattgccaaa aatttagtgg acaatgttgc taaagattat gtgcgactga 420
tgaagtatgg cgactctctc taccgctgca aacagctgaa gcgtgcggcc ctgggacgga 480
tgtgcacagt gatcaagagg cagaagcaga gtttggagta tttggagcaa gtgcgtcagc 540
atttatcccg tttgccaacc attgatccga ataccaggac cctgcttttg tgtgggtacc 600
caaatgttgg gaagtccagc ttcatcaaca aggtgacgag agcagacgtg gatgtccagc 660
cctatgcgtt cacaaccaag tctctgtttg ttgggcacat ggattataag tatctacgtt 720
ggcaggttgt agacactcct gggatcctgg accaccctct ggaggatagg aacaccatcg 780
agatgcaggc catcactgcc ctggcccacc tccgtgctgc ggtcctgtat gtgatggatt 840
tgtctgagca gtgtgggcat gggctgaggg agcagctaga actcttccag aacatcagac 900
ctctcttcat caacaagcct ctcatagttg tagccaacaa atgtgatgtg aagagaatag 960
ctgaactttc tgaagatgat cagaaaatat ttacagattt gcagtctgaa ggattccctg 1020
taatagagac cagcaccctg actgaggaag gtgttattaa agttaaaaca gaggcttgcg 1080
ataggctttt ggctcatcga gtggaaacca aaatgaaggg aaataaagtg aatgaggtgc 1140
tgaatagact gcacctggct atcccaacca ggagggacga taaggagagg ccccctttca 1200
tccctgaagg agtggtggct cgcaggaaga ggatggaaac tgaggagtcc aggaagaaga 1260
gggaacgaga tcttgagctg gaaatgggag atgattatat tttggatctt cagaagtact 1320
gggatttaat gaatttgtct gaaaaacatg ataagatacc agaaatctgg gaaggccata 1380
atatagctga ttatattgat ccagccatca tgaagaaatt ggaagaatta gaaaaagaag 1440
aagagctgag aacagctgct ggagagtatg acagtgtatc tgagagtgaa gacgaagaga 1500
tgctggaaat ccgacagctg gcaaagcaaa ttcgagagaa aaagaagttg aaaattctgg 1560
agtccaaaga aaagaataca cagggaccca ggatgccgcg aactgctaag aaggttcaga 1620
ggacagtttt ggagaaggag atgcgtagtc ttggtgttga catggacgat aaagacgatg 1680
cccattacgc agtccaggca agaagatccc ggagcatcac taggaaaaga aagcgggaag 1740
actctgctcc cccgtcctct gtggcccgga gtgggagttg ctctcgaact ccacgtgacg 1800
tttctggtct tagggatgtc aagatggtga agaaagccaa gactatgatg aagaatgctc 1860
agaagaagat gaatcggttg gggaagaaag gggaggcgga tagacacgtg tttgatatga 1920
agcccaagca cttgctgtct gggaagagga aagctggtaa aaaggacagg agatagtatc 1980
cgtttggttg gcgtggcttc gctagagtgt tgctgtttat ttcctggttt ggcacagtat 2040
ggtttcatga aattggagct ctgtataaac tgaaaaagac aaaataagta aagcacttgt 2100
tgctttgctg aaaactatgg ttaaccctat ataggtgtgg gaaatttttg tcactgcata 2160
atattacaaa tattttgagt agacagtgtt tccacattta atggagtatc agttgcttca 2220
gattttcaga actgggaaga tttactggtg taactgggtt gtttttgatg gagaaaaacc 2280
ttattttctt ttgtaagagc tgggagcaaa cacgtttatg agtgtgtcgg aatcccgtgc 2340
ttaaaatacg ctcttaaatt attttctagt cttattttac aatgtctcat tgtagtctgt 2400
cttcaactat tttatccaaa ataaacctcc agaagaaagt agttttcatt tacttagctc 2460
atgttttggt ttagttatag tcgctatgga tttggccaaa taaaaaggca aacaacaaaa 2520
aaaaaaaaaa aaaaaaa 2537
<210> 13
<211> 4386
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 13
atttaagcag gagcagcagc ctctgcagca gttggcacat ctgagaaggc agagattgaa 60
gagagtagga ggagcgtgca gcggcggtga cagtgccagg ccggagcggc tcaggccagc 120
gcaggtgcag gggctgcgag cgggtggagc gcgagggcgc tgggcgcagg gagcacggcc 180
ggtgggcggt gcagggcgca cggcgggcga gcagctgaca gcatcgtcac ggcggcggga 240
gggagtgcgc tgcgcctgcc tccgggagga gccgcatcca cacaccctgc gctgccctgt 300
cctgcgcgag tggagctctg aagaagctct gagcggagtt gtgttcttcc ccaggtgcgt 360
cctggctgag agttggagct ctccagcaac atgcctgagc agagtaacga ttaccgggtg 420
gccgtgtttg gggctggcgg tgttggcaag agctccctgg tgttgaggtt tgtgaaaggc 480
acattccggg agagctacat cccgacggtg gaagacacct accggcaagt gatcagctgt 540
gacaagagca tatgcacatt gcagatcacc gacacgacgg ggagccacca gttcccggcc 600
atgcagcggc tgtccatctc caaagggcac gccttcatcc tggtgtactc cattaccagc 660
cgacagtcct tggaggagct caagcccatc tacgaacaaa tctgcgagat caaaggggac 720
gtggagagca tccccatcat gctggtgggg aacaagtgtg atgagagccc cagccgcgag 780
gtgcagagca gcgaggcgga ggccttggcc cgcacatgga agtgtgcctt catggagacc 840
tcagccaagc tcaaccataa cgtgaaggag cttttccagg agctgctcaa cctggagaag 900
cgcaggaccg tgagtctcca gatcgacggg aaaaagagca agcagcagaa aaggaaagag 960
aagctcaaag gcaagtgcgt gatcatgtga aggcccttcc tgcgggagga gcagctgtgt 1020
gtccccggca cctcactccc ccaaaatgac acccaccgtc gtcagggtag catgtataat 1080
gcccacgtgt taaacattgc atttaatcga gatgcgtcct attgtcctta agagggcgtt 1140
tcacaccacc aacagtaagc cacccactct ggagtcacag aatctgccag gcggttcaag 1200
tgaaaaccaa cacactcagc atccctggga actgagaggt gccagcaatt gctgaaggtg 1260
gcgatgaaca cccgaaggtg ggagggagga ctggtaccca caaagcaaca tgtaccgaga 1320
ggactaaatg tcatctacgt gcatgtgaga gcgtgttaac ctagagttac ctgcaccaac 1380
cccagacaga agccaatcac atctttgggg gaggggaggg gcaggaagag gtgagaagat 1440
cagatggtcc aaagtggacc acacttggtc cattttacac ttttttaaag gggattaaaa 1500
aacacagcct ctcccccaaa gggtgtccgt tcttaattcc cacctggcct gttaggagcc 1560
ttgctaccct gaggggatgt gttcacctta cctagaccta gttaggaagt atcattttaa 1620
gctattagag tatttatctt catgtgcagg gataagtgca ctaacagtgt gctgctctgt 1680
cggaagttct tcagttttta agtgaggata tcgtgacagt attaaaacat cgcaataatg 1740
ttcctgtgtg ttatacatcg agggttttag aaatgtgatt ttcttctttt gacctgtgag 1800
gagtataact tctttcagcc ctcagatttt aaatacaagc aaataaactc actattttta 1860
gacgtttttt tcctccaagg tggttttctt ctcttaaata actcgatctg tacccagctg 1920
ggtagcagcc agcaaaggcc atcagacaac cagaagcaca tccatttttg tagtgtcaca 1980
aacatgtata tgccacactt tgcaccttaa tgaaatactt tgaaacagaa gttattcact 2040
gtgtttttga tgatctatct gtattggaaa tatgttcctg gaaaatgcat ttaaataata 2100
gtaaattctc ttgcatgttc cattatacgt gtcttctaag agctgttcaa tacagtattc 2160
actctagaaa caattatctt tttctcttaa tgattttgtg tgcatcttta atctttcaag 2220
ccaaattaca gctatttcag gtttcctgtg ttagcttggg gataggatgg tggctggaga 2280
caggcaggct tctctgccct gggaagagcc cactcagctt aattgctctg ccatcgtaga 2340
gcctggttgg acttggcttc ctgaaaactc ccactgatag tgcctgttag atctcctgtt 2400
tgtttcagtt ggcagaacat ttactggccc caactgtggc atcatcctct cagcagtctt 2460
cctgtcaccc gcctggcagg cagaaggagc tgcagtccca cgtgggcctg cctggggggg 2520
tgggggctgc atggctgttg ggtggcagtg tcagcacagg gagggcttaa gttggggatg 2580
tttgaccagg ccacctcctg caactgctgt ttctcctgtc cctcctatgc agggcttgca 2640
gcagcagcag tgtggccatc tccatccccc aaagcacact tgctctctca atatgtccta 2700
gttttcttca gccttttctg gttcagttcc cttgtcctga tctcatcctc tctggtctcc 2760
caataactca cccttgggat gtgtttagag cgtgggaggt gcctttgaga actgcttgac 2820
tccatgatct cctagaacaa aaccgccctg actttacagg gggaacactc atgctgagct 2880
gagaaagcag agaagtggcg tgggagccag ctgggggtga agagcatttg ggccagtccc 2940
gtggccccct tcagattcct caagcaggat tgttctgttc taaaaagctg ttgcacagca 3000
ttcgcaatga gatctttagt tggcggattt tctggaacat ttgtttttca acttgtcccg 3060
acattttttt tctgtttcta ttctgagaga gagatgatca agttttaatt tgggtatagg 3120
ttaaatggaa gaagaaacag aacttcatgg ccaaagtaga cctatagatt ttgattgggt 3180
tctttgttaa cagtagaatg cgatctttgc cactgactgt agtattaata aggttttaat 3240
gtgagatatt cctgcaaacc atcccatttc tactgattgt aagtcagaat ttcttttatc 3300
cctttcaaat cagtttctac atgtttaagt gttcagggct tcatcagcat gagaagtttg 3360
taattactga aagtctgatt tcattcagga cacatttttt ccttcatatt ttttctgtga 3420
atttataggc taggaaggct attgaagcct caattatggg tcttcatttt gagatcgttt 3480
tctatgagct gaactgagga tatcaatggt tatctcaaaa tcgtctttta ggagatcccc 3540
aattgactca gagtttgagg agttagtatc acagaattag atttttttaa agcatttgta 3600
cgtttccatt cccaaatatg tagctgtggt tcttgaaaac acatcctaca ttgcatatgg 3660
gcatagcagt ttttgaccca ggcagaataa gttaatattt aattaaatat tgctttgaag 3720
atggcgctct gggcatgagc atggggctcc atgacttccc ttctatcccc atgagcccct 3780
cctccatcca gcgacaagcc atgggcatgc atacaatgca gcaagaccaa cacaagagca 3840
atattgaatt gttcattcta tctaaaatta catgtatata aaatatataa tttatcttcc 3900
tgcatttttg aagtataaag tcataaattg tacatatctg taagctagta tatttgtttc 3960
actgtttgta atatttaaga aatgctcatt ctttgtagaa caaaaatgta ttaaatattt 4020
taaaaattgc tctgtgatac ttaatttttt tccccaaaat ttgtaatgtg ttgcttctac 4080
ataagttctc tggaaatatc tacaactaat aggacacatg taaatccttg aagacacatc 4140
ctggaattca taccccacaa ggacagtgtg tatacaaagt atttgcagag catgactttt 4200
atatgtgtgg gatatcaatg tgtatattta tatttaaagt gtatttattg ttacaagtct 4260
attctctatt atattttatt tactctgcgg ttataaaaat cacccttgca tacaagtttc 4320
tagttgccag tgatgttctg gaaataatgg gagatattac aataaagcta cagttatgac 4380
accctg 4386
<210> 14
<211> 2519
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 14
aatcttggtc gctaggacac ggctaacttc cgctttcttc cccctctcct aggctcaaac 60
tagtcaaatc ttgttcactc gaccaatggc aaatcggaag tgggcgggac ttcacaagtc 120
cggaccaaag aaacgcgagc ttagccctgg gtagcgcggc caatggccgt ggagcagccc 180
ctgtaaactg gctcgggcgc ccccacgccc gcccttcctt cttctcccag cattgccccc 240
cccacgtttc agcacagcgc tggccgcagt ctgacaggaa agggacggag ccaagatggc 300
ggcggccgac ggcgacgact cgctgtaccc catcgcggtg ctcatagacg aactccgcaa 360
tgaggacgtt cagcttcgcc tcaacagcat caagaagctg tccaccatcg ccttggccct 420
tggggttgaa aggacccgaa gtgagcttct gcctttcctt acagatacca tctatgatga 480
agatgaggtc ctcctggccc tggcagaaca gctgggaacc ttcactaccc tggtgggagg 540
cccagagtac gtgcactgcc tgctgccacc gctggagtcg ctggccacag tggaggagac 600
agtggtgcgg gacaaggcag tggagtcctt acgggccatc tcacacgagc actcgccctc 660
tgacctggag gcgcactttg tgccgctagt gaagcggctg gcgggcggcg actggttcac 720
ctcccgcacc tcggcctgcg gcctcttctc cgtctgctac ccccgagtgt ccagtgctgt 780
gaaggcggaa cttcgacagt acttccggaa cctgtgctca gatgacaccc ccatggtgcg 840
gcgggccgca gcctccaagc tgggggagtt tgccaaggtg ctggagctgg acaacgtcaa 900
gagtgagatc atccccatgt tctccaacct ggcctctgac gagcaggact cggtgcggct 960
gctggcggtg gaggcgtgcg tgaacatcgc ccagcttctg ccccaggagg atctggaggc 1020
cctggtgatg cccactctgc gccaggccgc tgaagacaag tcctggcgcg tccgctacat 1080
ggtggctgac aagttcacag agctccagaa agcagtgggg cctgagatca ccaagacaga 1140
cctggtccct gccttccaga acctgatgaa agactgtgag gccgaggtga gggccgcagc 1200
ctcccacaag gtcaaagagt tctgtgaaaa cctctcagct gactgtcggg agaatgtgat 1260
catgtcccag atcttgccct gcatcaagga gctggtgtcc gatgccaacc aacatgtcaa 1320
gtctgccctg gcctcagtca tcatgggtct ctctcccatc ttgggcaaag acaacaccat 1380
cgagcacctc ttgcccctct tcctggctca gctgaaggat gagtgccctg aggtacggct 1440
gaacatcatc tctaacctgg actgtgtgaa cgaggtgatt ggcatccggc agctgtccca 1500
gtccctgctc cctgccattg tggagctggc tgaggacgcc aagtggcggg tgcggctggc 1560
catcattgag tacatgcccc tcctggctgg acagctggga gtggagttct ttgatgagaa 1620
acttaactcc ttgtgcatgg cctggcttgt ggatcatgta tatgccatcc gcgaggcagc 1680
caccagcaac ctgaagaagc tagtggaaaa gtttgggaag gagtgggccc atgccacaat 1740
catccccaag gtcttggcca tgtccggaga ccccaactac ctgcaccgca tgactacgct 1800
cttctgcatc aatgtgctgt ctgaggtctg tgggcaggac atcaccacca agcacatgct 1860
acccacggtt ctgcgcatgg ctggggaccc ggttgccaat gtccgcttca atgtggccaa 1920
gtctctgcag aagatagggc ccatcctgga caacagcacc ttgcagagtg aagtcaagcc 1980
catcctagag aagctgaccc aggaccagga tgtggacgtc aaatactttg cccaggaggc 2040
tctgactgtt ctgtctctcg cctgatgctg gaagaggagc aaacactggc ctctggtgtc 2100
caccctccaa cccccacaag tccctctttg gggagacact ggggggcctt tggctgtcac 2160
tccctgtgca tggtctgacc ccaggcccct tcccccagca cggttcctcc tctccccagc 2220
ctgggaagat gtctcactgt ccacctccca acgggctagg ggagcacggg gttggacagg 2280
acagtgacct tgggaggaag gggctactcc gcccacgtca gggagagatg tgagcatccc 2340
gggtcactgg atcctgctgc tgtaatggga acccctcccc catttacttc tccacctccc 2400
gtcctcccca tcattggttt ttttttgtgt gtcaactgtg ccgtttttat tttattcctt 2460
ttattttccc ccttttcaca gagaaataaa ggtctagaag tagttggtca aaaaaaaaa 2519

Claims (10)

1.一种分子标记物,其特征在于,包含Prx1结合蛋白的一种或多种,所述Prx1结合蛋白为具有如SEQ ID NO.1~SEQ ID NO.7所示的氨基酸序列或如SEQ ID NO.1~SEQ ID NO.7所示的氨基酸序列经替换、缺失或插入一个或多个氨基酸得到的具有相同功能蛋白的氨基酸序列。
2.编码权利要求1所述的分子标记物的基因。
3.根据权利要求2所述的基因,其特征在于,其具有如下任意一种核苷酸序列:
(1)具有如SEQ ID NO.8~SEQ ID NO.14示的核苷酸序列;
(2)具有如SEQ ID NO.8~SEQ ID NO.14所示的核苷酸序列经一个或多个核苷酸的替换、缺失或插入得到的编码具有相同功能蛋白的核苷酸序列;
(3)在严格条件下,能够与SEQ ID NO.8~SEQ ID NO.14所示的核苷酸序列杂交的编码具有相同功能蛋白的核苷酸序列。
4.权利要求1所述的分子标记物或权利要求2或3所述的基因在辅助诊断和/或防治组织病变或肿瘤中的应用。
5.根据权利要求4所述的应用,其特征在于,所述组织病变为口腔癌前病变,优选为口腔白斑;所述肿瘤为口腔癌。
6.根据权利要求4或5所述的应用,其特征在于,所述防治组织病变或肿瘤为使用Prx1蛋白或Prx1结合蛋白的抑制剂和/或尼古丁中和剂或抑制剂。
7.权利要求1所述的分子标记物或权利要求2或3所述的基因在制备Prx1蛋白结合物中的应用。
8.权利要求1所述的分子标记物或权利要求2或3所述的基因在标记、鉴定、富集、分选和/或纯化Prx1高表达细胞中的应用。
9.一种包含权利要求1所述的分子标记物或权利要求2或3所述的基因的制剂。
10.根据权利要求9所述的制剂,其特征在于,其为药物或分子标记制剂。
CN201810462792.2A 2018-05-15 2018-05-15 过氧化物还原酶1结合蛋白及其应用 Active CN108949705B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810462792.2A CN108949705B (zh) 2018-05-15 2018-05-15 过氧化物还原酶1结合蛋白及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810462792.2A CN108949705B (zh) 2018-05-15 2018-05-15 过氧化物还原酶1结合蛋白及其应用

Publications (2)

Publication Number Publication Date
CN108949705A true CN108949705A (zh) 2018-12-07
CN108949705B CN108949705B (zh) 2021-10-26

Family

ID=64499171

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810462792.2A Active CN108949705B (zh) 2018-05-15 2018-05-15 过氧化物还原酶1结合蛋白及其应用

Country Status (1)

Country Link
CN (1) CN108949705B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108409851A (zh) * 2018-01-29 2018-08-17 上海交通大学 肾细胞癌中高水平表达的蛋白及其应用
CN112353939A (zh) * 2020-11-06 2021-02-12 中国农业科学院兰州兽医研究所 Gtpbp4蛋白作为免疫抑制剂的应用及敲低或过表达gtpbp4细胞系的构建

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103432574A (zh) * 2013-08-25 2013-12-11 浙江大学 一种过氧化物酶在制备防治脑血管疾病药物中的应用
CN107201372A (zh) * 2017-04-28 2017-09-26 中国水产科学研究院南海水产研究所 斑节对虾过氧化物还原酶1编码基因序列及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103432574A (zh) * 2013-08-25 2013-12-11 浙江大学 一种过氧化物酶在制备防治脑血管疾病药物中的应用
CN107201372A (zh) * 2017-04-28 2017-09-26 中国水产科学研究院南海水产研究所 斑节对虾过氧化物还原酶1编码基因序列及其用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DUNNILL CJ等: ""Homo sapiens mitogen-activated protein kinase kinase kinase 5 (MAP3K5), mRNA,Accession No: NM_005923.3"", 《GENBANK》 *
MOCI QI 等: ""Nicotine promotes the development of oral leukoplakia via regulating peroxiredoxin 1 and its binding proteins"", 《BRAZ J MED BIOL RES》 *
MOCI QI 等: ""Proteome profiling to identify peroxiredoxin 1 interacting protein partners in nicotine-associated oral leukoplakia"", 《ARCHIVES OF ORAL BIOLOGY》 *
SO YONG KIM等: ""A novel function of peroxiredoxin 1 (Prx-1) in apoptosis signal-regulating kinase 1 (ASK1)-mediated signaling pathway"", 《FEBS LETTERS》 *
张敏 等: ""Prx1基因敲除小鼠模型的构建"", 《北京口腔医学》 *
齐墨词 等: ""抗氧化蛋白 Prx1 在尼古丁诱导的口腔癌淋巴转移中的作用"", 《北京口腔医学》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108409851A (zh) * 2018-01-29 2018-08-17 上海交通大学 肾细胞癌中高水平表达的蛋白及其应用
CN108409851B (zh) * 2018-01-29 2020-12-08 上海交通大学 肾细胞癌中高水平表达的蛋白及其应用
CN112353939A (zh) * 2020-11-06 2021-02-12 中国农业科学院兰州兽医研究所 Gtpbp4蛋白作为免疫抑制剂的应用及敲低或过表达gtpbp4细胞系的构建
CN112353939B (zh) * 2020-11-06 2022-04-22 中国农业科学院兰州兽医研究所 Gtpbp4蛋白作为免疫抑制剂的应用及敲低或过表达gtpbp4细胞系的构建

Also Published As

Publication number Publication date
CN108949705B (zh) 2021-10-26

Similar Documents

Publication Publication Date Title
Sasaki et al. Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer
Izbeki et al. Loss of Kitlow progenitors, reduced stem cell factor and high oxidative stress underlie gastric dysfunction in progeric mice
CN107076746A (zh) 使用流形和超平面进行生物学数据的计算机分析
CN109072302A (zh) 非酒精性脂肪性肝炎的非侵入性诊断
JP2008503229A (ja) 骨ホメオスタシスを促進させる方法及び組成物
CN109490544A (zh) 一种用于检测人体免疫年龄的试剂盒及其应用
CN101027390B (zh) Lrp4/Corin多巴胺能神经元祖细胞标志物
CA2123856A1 (en) Diagnostic test and kit for disease or disorders in the digestive system
CN110488025A (zh) 一种化学发光定量检测粪便钙卫蛋白及其检测方法和其在肠道健康检测的用途
US20030215840A1 (en) Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 26156, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 or 6585 molecules
CN108949705A (zh) 过氧化物还原酶1结合蛋白及其应用
CN110283909A (zh) Zbtb20蛋白或其特异性抗体在贲门癌检测试剂盒中的应用
Mariotti et al. Comparison of radioassay and haemagglutination methods for anti-thyroid microsomal antibodies.
Sonnenfeld et al. Nerve growth factor receptors on dissociated neurofibroma Schwann-like cells
Tian et al. Correlative factors of insulin resistance in essential hypertension
JP2019216730A (ja) バイオセンサーを有するヒト細胞モデル
CN115469104A (zh) Hmgb1在胶质母细胞瘤tmz化疗预后预测中的应用
Ficková et al. Long lasting cadmium intake is associated with reduction of insulin receptors in rat adipocytes
CN101998989A (zh) Trpml3(mcoln3)作为咸味受体的鉴定及在用于鉴定调控钠转运、吸收或排泄和/或醛固酮和/或血管加压素的产生或释放的味觉(咸味)调节剂和/或治疗剂的测定中的用途
RU2438135C1 (ru) Способ иммуноцитохимической оценки пролиферативного состояния лимфоцитов по характеру экспрессии c-концевого фрагмента белка b23/нуклеофозмина в реакции непрямой иммунофлюоресценции
CN107779503A (zh) 阿尔茨海默相关的差异表达基因及其应用
Abdulkareem et al. Effects of indomethacin on expression of PTEN tumour suppressor in human cancers
Vercelli et al. Expression of Transforming Growth Factor‐β Isoforms in the Skin, Kidney, Pancreas and Bladder in a German Shepherd Dog affected by Renal Cystadenocarcinoma and Nodular Dermatofibrosis
JPH0630631B2 (ja) 生物学的液体中のジアミン類および/またはポリアミン類の存在を検出する診断試験キツト及び診断試験方法
CN100374864C (zh) 使用βig-h3蛋白质的诊断试剂盒

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant